{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:49:33Z","timestamp":1788922173671,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40122-025-00720-y","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T11:31:37Z","timestamp":1741779097000},"page":"957-969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Naldemedine Use and Healthcare Resource Utilization in Patients treated with Opioid Analgesics for Chronic Non-Cancer Pain: Results of a Real-world Study in the USA"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0220-0500","authenticated-orcid":false,"given":"Antonio","family":"De Vincentis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moscarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M. F.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Antonelli Incalzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"720_CR1","first-page":"1","volume":"2021","author":"JM Dahlhamer","year":"2019","unstructured":"Dahlhamer JM, Connor EM, Bose J, Lucas JL, Zelaya CE. Prescription opioid use among adults with chronic pain: United States. Natl Health Stat Report. 2019;2021:1\u20139.","journal-title":"Natl Health Stat Report"},{"key":"720_CR2","unstructured":"Opioids [Internet]. 2023 [cited 2024 Apr 26]. Available from: https:\/\/www.hopkinsmedicine.org\/health\/treatment-tests-and-therapies\/opioids."},{"key":"720_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11894-013-0344-2","volume":"15","author":"GA Ketwaroo","year":"2013","unstructured":"Ketwaroo GA, Cheng V, Lembo A. Opioid-induced bowel dysfunction. Curr Gastroenterol Rep. 2013;15:344.","journal-title":"Curr Gastroenterol Rep"},{"key":"720_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/15360280903098440","volume":"23","author":"SD Candrilli","year":"2009","unstructured":"Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother. 2009;23:231\u201341.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"720_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5055\/jom.2009.0014","volume":"5","author":"T Bell","year":"2009","unstructured":"Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag. 2009;5:137\u201344.","journal-title":"J Opioid Manag"},{"key":"720_CR6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s40122-021-00271-y","volume":"10","author":"G Varrassi","year":"2021","unstructured":"Varrassi G, Banerji V, Gianni W, Marinangeli F, Pinto C. Impact and consequences of opioid-induced constipation: a survey of patients. Pain Ther. 2021;10:1139\u201353.","journal-title":"Pain Ther"},{"key":"720_CR7","unstructured":"Sizar O, Genova R, Gupta M. Opioid-induced constipation. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Apr 26]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK493184\/."},{"key":"720_CR8","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1093\/pm\/pnaa152","volume":"21","author":"R Ouyang","year":"2020","unstructured":"Ouyang R, Li Z, Huang S, Liu J, Huang J. Efficacy and safety of peripherally acting mu-opioid receptor antagonists for the treatment of opioid-induced constipation: a Bayesian network meta-analysis. Pain Med. 2020;21:3224\u201332.","journal-title":"Pain Med"},{"key":"720_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S2468-1253(17)30105-X","volume":"2","author":"M Hale","year":"2017","unstructured":"Hale M, Wild J, Reddy J, Yamada T, Ferreira JCA. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials. Lancet Gastroenterol Hepatol. 2017;2:555\u201364.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"720_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1097\/j.pain.0000000000001174","volume":"159","author":"LR Webster","year":"2018","unstructured":"Webster LR, Nalamachu S, Morlion B, Reddy J, Baba Y, Yamada T, et al. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study. Pain. 2018;159:987.","journal-title":"Pain"},{"key":"720_CR11","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","volume":"35","author":"N Katakami","year":"2017","unstructured":"Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, et al. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2017;35:3859\u201366.","journal-title":"J Clin Oncol"},{"key":"720_CR12","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/annonc\/mdy118","volume":"29","author":"N Katakami","year":"2018","unstructured":"Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Ann Oncol. 2018;29:1461\u20137.","journal-title":"Ann Oncol"},{"key":"720_CR13","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1200\/JCO.24.00381","volume":"42","author":"J Hamano","year":"2024","unstructured":"Hamano J, Higashibata T, Kessoku T, Kajiura S, Hirakawa M, Oyamada S, et al. Naldemedine for opioid-induced constipation in patients with cancer: a multicenter, double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2024;42:4206\u201317.","journal-title":"J Clin Oncol"},{"key":"720_CR14","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.3390\/cancers14092112","volume":"14","author":"A Ozaki","year":"2022","unstructured":"Ozaki A, Kessoku T, Tanaka K, Yamamoto A, Takahashi K, Takeda Y, et al. Effectiveness of naldemedine compared with magnesium oxide in preventing opioid-induced constipation: a randomized controlled trial. Cancers (Basel). 2022;14:2112.","journal-title":"Cancers (Basel)"},{"key":"720_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"720_CR16","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","volume":"73","author":"DH Kim","year":"2018","unstructured":"Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring frailty in medicare data: development and validation of a claims-based frailty index. J Gerontol Ser A. 2018;73:980\u20137.","journal-title":"J Gerontol Ser A"},{"key":"720_CR17","unstructured":"Naldemedine_SmPC.pdf [Internet]. [cited 2024 Aug 16]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2019\/20190218143647\/anx_143647_en.pdf."},{"key":"720_CR18","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1248\/bpb.b23-00487","volume":"46","author":"M Yamada","year":"2023","unstructured":"Yamada M, Jimaru Y, Torii S, Mitsuba N, Takahashi K. A Retrospective observational study of factors affecting the efficacy of concurrent prescription of naldemedine for opioid-induced constipation caused by oxycodone tablets. Biol Pharm Bull. 2023;46:1826\u201331.","journal-title":"Biol Pharm Bull"},{"key":"720_CR19","volume":"16","author":"T Kessoku","year":"2024","unstructured":"Kessoku T, Higashibata T, Morioka Y, Naya N, Koretaka Y, Ichikawa Y, et al. Naldemedine and magnesium oxide as first-line medications for opioid-induced constipation: a comparative database study in Japanese patients with cancer pain. Cureus. 2024;16: e55925.","journal-title":"Cureus"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-025-00720-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-025-00720-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-025-00720-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T09:22:55Z","timestamp":1747473775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-025-00720-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["720"],"URL":"https:\/\/doi.org\/10.1007\/s40122-025-00720-y","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Antonio De Vincentis and Raffaele Antonelli Incalzi have no conflicts of interest to declare with the present study. Bin Cai, Marco Moscarda, and Peter Barnes are employees of Shionogi at the time of writing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study is conducted only using an existing anonymous, commercially available secondary healthcare claims database that meets the US Health Insurance Portability and Accountability Act (HIPAA) requirement. Therefore, the data do not meet the definition of human subject research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}